Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:3. https://doi.org/10.3322/caac.21660.
Google ScholarÂ
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:11. https://doi.org/10.1038/nrc4019.
Google ScholarÂ
Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD. Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst. 2018;110:7. https://doi.org/10.1093/jnci/djy085.
Google ScholarÂ
Ngoi NY, Sundararajan V, Tan DS. Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int J Gynecol Cancer. 2020. https://doi.org/10.1136/ijgc-2020-001277.
Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18:622–36. https://doi.org/10.1038/nrm.2017.67.
Google ScholarÂ
Toledo L, Neelsen KJ, Lukas J. Replication catastrophe: when a checkpoint fails because of exhaustion. Mol Cell. 2017;66:6. https://doi.org/10.1016/j.molcel.2017.05.001.
Google ScholarÂ
Gorgoulis VG, Vassiliou LVF, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13. https://doi.org/10.1038/nature03485.
Google ScholarÂ
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–7. https://doi.org/10.1038/nature05268.
Google ScholarÂ
Bartkova J, Horejsà Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70. https://doi.org/10.1038/nature03482.
Google ScholarÂ
Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352–5. https://doi.org/10.1126/science.1140735.
Google ScholarÂ
Ngoi NYL, Pilié PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21:278–93. https://doi.org/10.1038/s41571-024-00863-5.
Google ScholarÂ
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Res. 2023;29:2800–7. https://doi.org/10.1158/1078-0432.CCR-22-2444.
Google ScholarÂ
Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017. https://doi.org/10.1101/gad.290957.116.
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:16. https://doi.org/10.1158/1078-0432.CCR-08-0196.
Google ScholarÂ
Tan TZ, Miow QH, Huang RYJ, Wong MK, Ye J, Lau JA, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer: a subtyping scheme for epithelial ovarian cancer. EMBO Mol Med. 2013;5:7. https://doi.org/10.1002/emmm.201201823.
Google ScholarÂ
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:7353. https://doi.org/10.1038/nature10166.
Google ScholarÂ
Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19:26–38. https://doi.org/10.1158/1535-7163.MCT-19-0019.
Google ScholarÂ
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:7. https://doi.org/10.1038/nmeth.2089.
Google ScholarÂ
Davarinejad H. Quantifications of western blots with ImageJ. University of York; 2015.
Kilgas S, Kiltie AE, Ramadan K. Immunofluorescence microscopy-based detection of ssDNA foci by BrdU in mammalian cells. STAR Protoc. 2021;2:4. https://doi.org/10.1016/j.xpro.2021.100978.
Google ScholarÂ
Elfar GA, Aning O, Ngai TW, Yeo P, Chan JWK, Sim SH, et al. p53-dependent crosstalk between DNA replication integrity and redox metabolism mediated through a NRF2-PARP1 axis. Nucleic Acids Res. 2024;52:12351–77. https://doi.org/10.1093/nar/gkae811.
Google ScholarÂ
Gyori BM, Venkatachalam G, Thiagarajan PS, Hsu D, Clement MV. OpenComet: an automated tool for comet assay image analysis. Redox Biol. 2014;2:457–65. https://doi.org/10.1016/j.redox.2013.12.020.
Google ScholarÂ
McGrail DJ, Lin CCJ, Dai H, Mo W, Li Y, Stephan C, et al. Defective replication stress response is inherently linked to the cancer stem cell phenotype. Cell Rep. 2018;23:7. https://doi.org/10.1016/j.celrep.2018.04.068.
Google ScholarÂ
Tan TZ, Heong V, Ye J, Lim D, Low J, Choolani M, et al. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer. J Pathol. 2019;247:3. https://doi.org/10.1002/path.5191.
Google ScholarÂ
Nguyen HTL, Nguyen ST, Van Pham P. Concise Review: 3D cell culture systems for anticancer drug screening. Biomed Res Ther. 2016;3:22. https://doi.org/10.7603/s40730-016-0022-8.
Google ScholarÂ
Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–68. https://doi.org/10.1074/jbc.273.10.5858.
Google ScholarÂ
Rodriguez-Acebes S, Mourón S, Méndez J. Uncoupling fork speed and origin activity to identify the primary cause of replicative stress phenotypes. J Biol Chem. 2018;293:12855–61. https://doi.org/10.1074/jbc.RA118.003740.
Google ScholarÂ
Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA. 2010;107:16090–5. https://doi.org/10.1073/pnas.1005031107.
Google ScholarÂ
Yekezare M, Gómez-González B, Diffley JFX. Controlling DNA replication origins in response to DNA damage – inhibit globally, activate locally. J Cell Sci. 2013;126:1297–306. https://doi.org/10.1242/jcs.096701.
Google ScholarÂ
Genois MM, Gagné JP, Yasuhara T, Jackson J, Saxena S, Langelier MF, et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1. Mol Cell. 2021;81:784–800.e8. https://doi.org/10.1016/j.molcel.2020.12.010.
Google ScholarÂ
Rimmelé P, Komatsu J, Hupé P, Roulin C, Barillot E, Dutreix M, et al. Spi-1/PU.1 oncogene accelerates DNA replication fork elongation and promotes genetic instability in the absence of DNA breakage. Cancer Res. 2010;70:6757–66. https://doi.org/10.1158/0008-5472.CAN-09-4691.
Google ScholarÂ
Sarni D, Barroso S, Shtrikman A, Irony-Tur Sinai M, Oren YS, Aguilera A, et al. Topoisomerase 1-dependent R-loop deficiency drives accelerated replication and genomic instability. Cell Rep. 2022;40:111397. https://doi.org/10.1016/j.celrep.2022.111397.
Google ScholarÂ
Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279–84. https://doi.org/10.1038/s41586-018-0261-5.
Google ScholarÂ
Mansilla SF, Bertolin AP, Bergoglio V, Pillaire MJ, González Besteiro MA, Luzzani C, et al. Cyclin Kinase-independent role of p21CDKN1A in the promotion of nascent DNA elongation in unstressed cells. Botchan MR, editor. eLife. 2016;5:e18020. https://doi.org/10.7554/eLife.18020.
Simoneschi D, Rona G, Zhou N, Jeong YT, Jiang S, Milletti G, et al. CRL4AMBRA1 is a master regulator of D-type cyclins. Nature. 2021;592:789–93. https://doi.org/10.1038/s41586-021-03445-y.
Google ScholarÂ
Maiani E, Milletti G, Nazio F, Holdgaard SG, Bartkova J, Rizza S, et al. AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021;592:799–803. https://doi.org/10.1038/s41586-021-03422-5.
Google ScholarÂ
Chaikovsky AC, Li C, Jeng EE, Loebell S, Lee MC, Murray CW, et al. The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D. Nature. 2021;592:794–8. https://doi.org/10.1038/s41586-021-03474-7.
Google ScholarÂ
Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, Bétous R, et al. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 2013;27:1610. https://doi.org/10.1101/gad.214080.113.
Google ScholarÂ
Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, et al. Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol. 2021;163:246–53. https://doi.org/10.1016/j.ygyno.2021.08.024.
Google ScholarÂ
Simpkins F, Nasioudis D, Wethington SL, Martin LP, Tanyi JL, Latif NA, et al. Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). J Clin Oncol. 2024;42:5510. https://doi.org/10.1200/JCO.2024.42.16_suppl.5510.
Google ScholarÂ
Banerjee S, Stewart J, Porta N, Toms C, Leary A, Lheureux S, et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). Int J Gynecol Cancer. 2021;31:1471–5. https://doi.org/10.1136/ijgc-2021-002973.
Google ScholarÂ
Xu H, George E, Gallo D, Medvedev S, Wang X, Datta A, et al. Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Nat Commun. 2025:3112. https://doi.org/10.1038/s41467-025-58183-w.
Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:7. https://doi.org/10.1016/S1470-2045(20)30180-7.
Google ScholarÂ
McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021;13:eabe6201. https://doi.org/10.1126/scitranslmed.abe6201.
Google ScholarÂ
Azzoni V, Wicinski J, Macario M, Castagné M, Finetti P, Ambrosova K, et al. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death Dis. 2022;13:96. https://doi.org/10.1038/s41419-022-04538-w.
Google ScholarÂ
Schuhwerk H, Kleemann J, Gupta P, van Roey R, Armstark I, Kreileder M, et al. The EMT transcription factor ZEB1 governs a fitness-promoting but vulnerable DNA replication stress response. Cell Rep. 2022;41:11. https://doi.org/10.1016/j.celrep.2022.111819.
Google ScholarÂ
Sundararajan V, Tan TZ, Lim D, Peng Y, Wengner AM, Ngoi NYL, et al. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition. J Pathol. 2023;259:2. https://doi.org/10.1002/path.6032.
Google ScholarÂ
Heitmeir B, Deniz M, Janni W, Rack B, Schochter F, Wiesmüller L. Circulating tumor cells in breast cancer patients: a balancing act between stemness, EMT features and DNA damage responses. Cancers. 2022;14:997. https://doi.org/10.3390/cancers14040997.
Google ScholarÂ
Hu Y, Taylor-Harding B, Raz Y, Haro M, Recouvreux MS, Taylan E, et al. Are epithelial ovarian cancers of the mesenchymal subtype actually intraperitoneal metastases to the ovary? Front Cell Dev Biol. 2020;8:647. https://doi.org/10.3389/fcell.2020.00647.
Google ScholarÂ
Torres D, Kumar A, Bakkum-Gamez JN, Weaver AL, McGree ME, Wang C, et al. Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2019;152:223–7. https://doi.org/10.1016/j.ygyno.2018.11.019.
Google ScholarÂ
Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134:e175369. https://doi.org/10.1172/JCI175369.
Google ScholarÂ
Fontana E, Rosen E, Lee EK, Højgaard M, Mettu NB, Lheureux S, et al. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst. 2024;116:1439–49. https://doi.org/10.1093/jnci/djae098.
Google ScholarÂ
Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, et al. First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res. 2024;30:2057–67. https://doi.org/10.1158/1078-0432.CCR-23-2409.
Google ScholarÂ
Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, et al. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Sci Signal. 2016;9:448. https://doi.org/10.1126/scisignal.aaf8175.
Google ScholarÂ
Tan M, Asad M, Heong V, Wong MK, Tan TZ, Ye J, et al. The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. Mol Oncol. 2019;13:4. https://doi.org/10.1002/1878-0261.12425.
Google ScholarÂ
Yeo XH, Sundararajan V, Wu Z, Phua ZJC, Ho YY, Peh KLE, et al. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer. Commun Biol. 2023;6:660. https://doi.org/10.1038/s42003-023-05045-0.
Google ScholarÂ
Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res. 2017;23:3794–801. https://doi.org/10.1158/1078-0432.CCR-16-2196.
Google ScholarÂ
King D, Southgate HED, Roetschke S, Gravells P, Fields L, Watson JB, et al. Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells. Cancers. 2021;13:6215. https://doi.org/10.3390/cancers13246215.
Google ScholarÂ
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8:1404–21. https://doi.org/10.1158/2159-8290.CD-18-0474.
Google ScholarÂ
